Metabolic

5 compounds in this category.

AOD-9604

Category 1

Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191

A modified fragment of human growth hormone (amino acids 177-191) originally developed as an anti-obesity agent. Targets

Route

SubQ

Dose

300–500 mcg

Cycle

12–16 weeks

Fat lossMetabolic healthBody composition improvement

Amlexanox

Unregulated

Aphthasol, OraDisc A

An anti-inflammatory and anti-allergic compound originally approved for treating aphthous ulcers (canker sores). Gained

Route

Oral tablet or topical

Dose

25–50 mg (oral, investigational for metabolic use)

Cycle

8–12 weeks

Metabolic optimization researchInsulin sensitivity improvementFat loss support (investigational)

Setmelanotide

FDA Approved

Imcivree, RM-493

An MC4R (melanocortin 4 receptor) agonist FDA-approved for rare genetic obesity disorders including POMC, PCSK1, and LEP

Route

SubQ

Dose

1–3 mg (titrated)

Cycle

Ongoing

Rare genetic obesity (POMC deficiency)PCSK1 deficiency obesityLEPR deficiency obesity

Tesofensine

Investigational

NS2330, TE

A triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine) originally developed for Parkinson's and Alz

Route

Oral

Dose

0.25–0.5 mg

Cycle

Ongoing

Weight management (investigational)Appetite suppressionMetabolic rate enhancement

Pramlintide

FDA Approved

Symlin, Amylin Analog

A synthetic analog of amylin, a peptide hormone co-secreted with insulin by pancreatic beta cells. FDA-approved as an ad

Route

SubQ

Dose

15–120 mcg (titrated by diabetes type)

Cycle

Ongoing

Type 1 diabetes (adjunct to insulin)Type 2 diabetes (adjunct to insulin)Postprandial glucose control

All Categories